CRISPR Therapeutics (CRSP) Expected to Announce Earnings on Monday

CRISPR Therapeutics (NASDAQ:CRSP) will likely be releasing its Q2 2025 earnings data before the market opens on Monday, August 4th. Analysts expect CRISPR Therapeutics to post earnings of ($1.54) per share and revenue of $6.44 million for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 1,023.64% and a negative return on equity of 20.08%. During the same quarter in the prior year, the business posted ($1.43) EPS. The firm’s revenue was up 71.6% compared to the same quarter last year. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Price Performance

CRSP stock opened at $56.09 on Friday. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $71.13. The firm has a fifty day moving average price of $49.63 and a two-hundred day moving average price of $43.36. The firm has a market cap of $4.84 billion, a price-to-earnings ratio of -12.41 and a beta of 1.80.

Insider Activity

In related news, Director Simeon George acquired 989,812 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, July 16th. The stock was acquired at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the completion of the acquisition, the director directly owned 1,730,179 shares of the company’s stock, valued at $90,021,213.37. This trade represents a 133.69% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Naimish Patel sold 3,932 shares of the company’s stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the sale, the insider directly owned 6,068 shares of the company’s stock, valued at $218,083.92. The trade was a 39.32% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new stake in CRISPR Therapeutics in the 1st quarter valued at about $861,000. Woodline Partners LP lifted its holdings in CRISPR Therapeutics by 34.3% in the 1st quarter. Woodline Partners LP now owns 136,483 shares of the company’s stock valued at $4,645,000 after acquiring an additional 34,883 shares during the last quarter. Finally, Royal Bank of Canada lifted its holdings in CRISPR Therapeutics by 28.2% in the 1st quarter. Royal Bank of Canada now owns 142,696 shares of the company’s stock valued at $4,856,000 after acquiring an additional 31,392 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on CRSP. The Goldman Sachs Group lowered their target price on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a “neutral” rating for the company in a research note on Thursday, May 8th. Chardan Capital restated a “buy” rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, June 26th. HC Wainwright restated a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Barclays lowered their price target on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating for the company in a research report on Friday, May 9th. Finally, JMP Securities restated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $71.31.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.